Unknown

Dataset Information

0

Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.


ABSTRACT: AIMS: To report the first three studies with SCH 900435, a selective glycine-1 re-uptake inhibitor in development for treating schizophrenia, using systematic evaluations of pharmacodynamics to understand the observed effects. METHODS: Three double-blind, placebo-controlled studies (single, visual effect and multiple dose) were performed. In the single and multiple dose study SCH 900435 (0.5-30?mg) was given to healthy males and frequent pharmacokinetic and pharmacodynamic measurements were performed. The visual effects study incorporated visual electrophysiological measures of macular, retinal and intracranial visual pathway function. RESULTS: In the single dose study (highest difference, 95% CI, P) increases in smooth pursuit eye movements (8, 12?mg (-6.09, 10.14, -2.04, 0.013), 30?mg), pupil?:?iris ratio (20 and 30?mg (-0.065, 0.09, -0.04, <0.0001)), VAS colour perception (30?mg (-9.48, 13.05, -5.91, <0.0001)) and changes in spontaneous reports of visual disturbance were found, while FSH (8?mg (0.42, 0.18, 0.66, 0.0015), 12, 20?mg), LH (8-30?mg (1.35, 0.65, 2.05, 0.0003)) and EEG alpha2 activity decreased (12, 20, 30?mg (0.27, 0.14, 0.41, 0.0002)). A subsequent dedicated visual effects study demonstrated that visual effects were transient without underlying electrophysiological changes. This provided enough safety information for starting a multiple ascending dose study, showing less visual symptoms after twice daily dosing and titration, possibly due to tolerance. CONCLUSIONS: Several central nervous system (CNS) effects and gonadotropic changes resulted from administration of 8?mg and higher, providing evidence for CNS penetration and pharmacological activity of SCH 900435. Antipsychotic activity in patients, specificity of the reported effects for this drug class and possible tolerance to visual symptoms remain to be established.

SUBMITTER: Liem-Moolenaar M 

PROVIDER: S-EPMC3690104 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.

Liem-Moolenaar Marieke M   Peeters Pierre P   Kamerling Ingrid M C IM   Hogg Chris C   Holder Graham G   Kleijn Huub Jan HJ   Spaans Edwin E   Udo De Haes Joanna J   de Kam Marieke L ML   Franson Kari L KL   Cohen Adam F AF   van Gerven Joop M A JM  

British journal of clinical pharmacology 20130601 6


<h4>Aims</h4>To report the first three studies with SCH 900435, a selective glycine-1 re-uptake inhibitor in development for treating schizophrenia, using systematic evaluations of pharmacodynamics to understand the observed effects.<h4>Methods</h4>Three double-blind, placebo-controlled studies (single, visual effect and multiple dose) were performed. In the single and multiple dose study SCH 900435 (0.5-30 mg) was given to healthy males and frequent pharmacokinetic and pharmacodynamic measureme  ...[more]

Similar Datasets

| S-EPMC8230656 | biostudies-literature
| S-EPMC5256683 | biostudies-literature
| S-EPMC5516583 | biostudies-literature
| S-EPMC8094926 | biostudies-literature
| S-EPMC11195145 | biostudies-literature
| S-EPMC8987148 | biostudies-literature
2024-12-31 | E-MTAB-12982 | biostudies-arrayexpress
2015-07-16 | PXD001285 | Pride
| S-EPMC7609514 | biostudies-literature
| S-EPMC7855417 | biostudies-literature